Utility of <scp>PAX</scp>8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal <scp>PAX</scp>8 antibody

Toriyama, Akane; Mori, Takashi; Sekine, Shigeki; Yoshida, Akihiko; Hino, Okio; Tsuta, Koji

doi:10.1111/his.12405

Cited by 45 publications

(39 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the result of staining for PAX8 can be positive for thymic carcinomas when a polyclonal antibody is used, this likely results from cross-reactivity to another PAX gene product, which is not reproduced when a monoclonal antibody is used. 169 More than IHC staining, clinical and radiologic correlation is important to confirm whether a tumor is arising in the lung or in the thymus.…”

Section: Squamous Cell Carcinomamentioning

confidence: 99%

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

Yatabe

Đačić

Borczuk

et al. 2019

Journal of Thoracic Oncology

Self Cite

242

221

View full text Add to dashboard Cite

Since the 2015 WHO classification was introduced into clinical practice, immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small cell versus non-small cell carcinoma, patients' treatment of choice is directly linked to histologic subtypes of non-small cell carcinoma, which pertains to IHC results, particularly for poorly differentiated tumors. The use of IHC has improved diagnostic accuracy in the classification of lung carcinoma, but the interpretation of IHC results remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several International Association for the Study of Lung Cancer Pathology Committee meetings, the issues and caveats were summarized in terms of 11 key questions covering common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors. This article provides answers and explanations for the key questions about the use of IHC in diagnosis of lung carcinoma, representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.

show abstract

Section: Squamous Cell Carcinomamentioning

confidence: 99%

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

Yatabe

Đačić

Borczuk

et al. 2019

Journal of Thoracic Oncology

Self Cite

242

221

View full text Add to dashboard Cite

show abstract

“…In fact, using more specific monoclonal anti-PAX-8 antibodies, it has been demonstrated unequivocally that PAX-8 is not expressed in thymic tumors or lymphomas. [10][11][12] The lesson of this unfortunate ''mischaracterization'' of PAX-8 by using antibodies of inferior specificity is that it is quite important for the pathologist performing immunohistochemistry to have reasonable certainty about the specificity of the antibodies being employed in the laboratory. In the case of the cross-reacting PAX-8 antibodies, overreliance on the information provided by the vendor was partly responsible.…”

Section: Independent Organizationsmentioning

confidence: 99%

Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It

Gown

2016

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.—There are a number of critical factors that can lead to incorrect results if the diagnostic pathologist performing immunohistochemistry is unaware of, or not vigilant about, their influence. Objective.—To highlight 3 arenas in which errors may be introduced. Data Sources.—For choosing the correct primary antibody, selection of the most appropriate antibodies for a given clinical application can be aided by obtaining information from the vendor; however, this can yield incomplete information. There are a number of online databases that have comparisons of antibodies from different vendors, particularly with respect to their use and properties. Reading the published literature can assist in this process, particularly with respect to determining antibody sensitivity and specificity, but it is a daunting task to keep up with all of the immunohistochemistry-related papers published. Finally, Web sites of a number of quality assurance organizations are accessible and can provide a wealth of information comparing the “real world” performance characteristics of different antibodies to the same target protein. False-positive signals can result from a number of factors, including the use of inappropriately high antibody concentration, and “pseudospecific” signal that is in the wrong compartment of the cell. False-negative signal can result from factors such as use of a nonoptimized epitope retrieval method. It is critical that epitope retrieval methods be optimized for each antibody employed in the laboratory. Conclusions.—By paying attention to these potential problems, the “black box” of diagnostic immunohistochemistry can be made more transparent.

show abstract

“…Some studies have reported PAX8 positivity in RMC, with polyclonal or unknown antibodies.9.13,16 It is necessary to know the differences in PAX8 antibody specificities. Polyclonal PAX8 antibody cross‐reacts with some of the other members of the PAX family . We have already evaluated the utility of a PAX8 monoclonal antibody .…”

Section: Discussionmentioning

confidence: 99%

Renal medullary carcinoma in a young mixed‐race man in Japan

Toriyama

Izumi

Tomita

et al. 2019

Pathology International

Self Cite

View full text Add to dashboard Cite

Renal medullary carcinoma (RMC) is a rare and aggressive cancer associated with the sickle cell trait. The diagnosis of RMC depends on recognition of its histologic features and immunohistochemical deficiency of INI1, but correct diagnosis is sometimes difficult, especially if a patient's information on race, past, and family medical history is unclear. At present, this is the first report on RMC in Japan.

show abstract

Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody

Abstract: Monoclonal PAX8 antibody showed high specificity to thyroid tumours and was superior to the polyclonal antibody.

Cited by 45 publications

References 18 publications

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It

Renal medullary carcinoma in a young mixed‐race man in Japan

Contact Info

Product

Resources

About